Haifeng Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Haifeng Wang has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
Tianyi Liu
Department of Neurosurgery, The Second Hospital of Jilin University, Changchun, 130041, P. R. China
5 shared publicationsWenchen Li
Department of Neurosurgery, The Second Hospital of Jilin University, Changchun, Jilin Province, China
4 shared publicationsWenhao Zhu
Department of Neurosurgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310016, China
4 shared publications- Peibiao Zhang
Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China
3 shared publications Wenzhong Li
Department of Neurosurgery, The Second Hospital of Jilin University, Changchun, 130041, P. R. China
3 shared publicationsXiaoyu Zhang
Department of Neurosurgery, The Second Hospital of Jilin University, Changchun, 130041, P. R. China
3 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by Wolters Kluwer Health in Neural Regeneration Research
Brain renin–angiotensin system: Pathophysiological mechanisms and therapeutic targets in ischemic stroke
This review aims to delineate the context-dependent, opposing actions of the angiotensin II type 1 receptor, angiotensin II type 2 receptor, and angiotensin-converting enzyme 2/ angiotensin-(1–7)/Mas receptor axis in ischemic stroke and to discuss their translational potential for neuroprotective therapy. Although recanalization cannot guarantee favorable functional outcomes for all patients with ischemic stroke, adjunctive neuroprotective targets remain limited. Dysregulation of the brain renin–angiotensin system is increasingly recognized as a potentially modifiable pathway in post-stroke brain injury. Cerebral ischemia shifts the physiological receptor balance toward angiotensin II type 1 receptor predominance, promoting vasoconstriction, blood–brain barrier disruption, neuroinflammation, excitotoxicity, mitochondrial dysfunction, and apoptosis. Conversely, the angiotensin II type 2 receptor and Mas receptor may counter these detrimental processes through temporally distinct mechanisms. The angiotensin II type 2 receptor may provide early neuroprotection through endothelial nitric oxide synthase-mediated vasodilation, suppression of nicotinamide adenine dinucleotide phosphate oxidase, and inhibition of nuclear factor kappa-B signaling. By comparison, Mas receptor activation may facilitate delayed brain repair through mitochondrial stabilization, nuclear factor erythroid 2-related factor 2-mediated antioxidant responses, and preservation of blood–brain barrier integrity. This temporal framework, characterized by acute injury associated with angiotensin II type 1 receptor signaling, early protection associated with angiotensin II type 2 receptor signaling, and long-term recovery potentially supported by Mas receptor signaling, provides a rationale for time-sensitive therapeutic strategies. Preclinical evidence supports the neuroprotective effects of angiotensin II type 1 receptor blockers. Angiotensin II type 2 receptor agonists, such as compound 21, and glycosylated angiotensin-(1–7) peptide derivatives are promising approaches for engaging endogenous protective pathways.
- 13 November 2026
- Published by Wolters Kluwer Health in Neural Regeneration Research
Open AccessBrain renin–angiotensin system: Pathophysiological mechanisms and therapeutic targets in ischemic stroke
This review aims to delineate the context-dependent, opposing actions of the angiotensin II type 1 receptor, angiotensin II type 2 receptor, and angiotensin-converting enzyme 2/ angiotensin-(1–7)/Mas receptor axis in ischemic stroke and to discuss their translational potential for neuroprotective therapy. Although recanalization cannot guarantee favorable functional outcomes for all patients with ischemic stroke, adjunctive neuroprotective targets remain limited. Dysregulation of the brain renin–angiotensin system is increasingly recognized as a potentially modifiable pathway in post-stroke brain injury. Cerebral ischemia shifts the physiological receptor balance toward angiotensin II type 1 receptor predominance, promoting vasoconstriction, blood–brain barrier disruption, neuroinflammation, excitotoxicity, mitochondrial dysfunction, and apoptosis. Conversely, the angiotensin II type 2 receptor and Mas receptor may counter these detrimental processes through temporally distinct mechanisms. The angiotensin II type 2 receptor may provide early neuroprotection through endothelial nitric oxide synthase-mediated vasodilation, suppression of nicotinamide adenine dinucleotide phosphate oxidase, and inhibition of nuclear factor kappa-B signaling. By comparison, Mas receptor activation may facilitate delayed brain repair through mitochondrial stabilization, nuclear factor erythroid 2-related factor 2-mediated antioxidant responses, and preservation of blood–brain barrier integrity. This temporal framework, characterized by acute injury associated with angiotensin II type 1 receptor signaling, early protection associated with angiotensin II type 2 receptor signaling, and long-term recovery potentially supported by Mas receptor signaling, provides a rationale for time-sensitive therapeutic strategies. Preclinical evidence supports the neuroprotective effects of angiotensin II type 1 receptor blockers. Angiotensin II type 2 receptor agonists, such as compound 21, and glycosylated angiotensin-(1–7) peptide derivatives are promising approaches for engaging endogenous protective pathways.
- Open Access
- 14 January 2026
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 19, 1647046
Multivariate genetic architecture of poor sleep quality
The field of genetics has yet to elucidate the complex genetic underpinnings that influence sleep quality. Previous studies have conducted genome-wide association studies (GWAS) on different dimensions of sleep health, but have not directly analyzed the multivariate genetic structure of poor sleep quality (PSQ). To address this knowledge gap, we employed a multifaceted approach that incorporated Genomic Structural Equation Modeling (Genomic-SEM) and multiple Post-GWAS methods. This strategy enabled us to identify causal single nucleotide polymorphisms (SNPs) that contribute to the variability in poor sleep quality. Our study identified a total of 14 leading SNP loci (such as rs2820309) and 3 fine-mapping significant loci (such as KTN1: rs77168063). To further investigate the underlying mechanisms, we employed multiple whole-transcriptome association methods. These methods analyzed susceptible gene signal loci that exhibited strong correlation with poor sleep quality, as determined by tissue, cell layer, and genome component analysis, along with related component information. Subsequently, data on approximately 13,000 common diseases were evaluated to determine the associated predisposing factors for poor sleep quality, and the correlation between poor sleep quality and 20 common neurological diseases was assessed. Additionally, we utilized a polygenic score based on summary data to analyze evidence of risk for poor sleep quality across different chromosomes. This study offers a novel perspective on the genetic underpinnings of poor sleep quality by conducting a genome-wide association study for a phenotype that was not directly measured.
- 14 January 2026
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 19, 1647046
Open AccessMultivariate genetic architecture of poor sleep quality
The field of genetics has yet to elucidate the complex genetic underpinnings that influence sleep quality. Previous studies have conducted genome-wide association studies (GWAS) on different dimensions of sleep health, but have not directly analyzed the multivariate genetic structure of poor sleep quality (PSQ). To address this knowledge gap, we employed a multifaceted approach that incorporated Genomic Structural Equation Modeling (Genomic-SEM) and multiple Post-GWAS methods. This strategy enabled us to identify causal single nucleotide polymorphisms (SNPs) that contribute to the variability in poor sleep quality. Our study identified a total of 14 leading SNP loci (such as rs2820309) and 3 fine-mapping significant loci (such as KTN1: rs77168063). To further investigate the underlying mechanisms, we employed multiple whole-transcriptome association methods. These methods analyzed susceptible gene signal loci that exhibited strong correlation with poor sleep quality, as determined by tissue, cell layer, and genome component analysis, along with related component information. Subsequently, data on approximately 13,000 common diseases were evaluated to determine the associated predisposing factors for poor sleep quality, and the correlation between poor sleep quality and 20 common neurological diseases was assessed. Additionally, we utilized a polygenic score based on summary data to analyze evidence of risk for poor sleep quality across different chromosomes. This study offers a novel perspective on the genetic underpinnings of poor sleep quality by conducting a genome-wide association study for a phenotype that was not directly measured.
- Open Access
- 3 September 2025
- Published by Ivyspring International Publisher in Theranostics
- Vol. 15 (18) , 9775-9792
Enhancing glymphatic transport through angiotensin II type 2 receptor activation promotes neurological recovery after traumatic brain injury
Background: Traumatic brain injury (TBI) may impair the function of the glymphatic system, leading to diminished metabolic waste clearance and aggravated neurological deficits. While angiotensin II type 2 receptor (AT2R) activation has demonstrated neuroprotective effects, its specific impact on the glymphatic system following TBI remains uncharacterized.
- 3 September 2025
- Published by Ivyspring International Publisher in Theranostics
- Vol. 15 (18) , 9775-9792
Open AccessEnhancing glymphatic transport through angiotensin II type 2 receptor activation promotes neurological recovery after traumatic brain injury
Background: Traumatic brain injury (TBI) may impair the function of the glymphatic system, leading to diminished metabolic waste clearance and aggravated neurological deficits. While angiotensin II type 2 receptor (AT2R) activation has demonstrated neuroprotective effects, its specific impact on the glymphatic system following TBI remains uncharacterized.
- Open Access
- 6 August 2025
- Published by Elsevier in Materials Today Bio
- Vol. 34, 102172
Neuroactive network tissue based on dual-factor neuroregenerative bioactive coating scaffolds and neural stem cells for spinal cord injury repair
- 6 August 2025
- Published by Elsevier in Materials Today Bio
- Vol. 34, 102172
Open AccessNeuroactive network tissue based on dual-factor neuroregenerative bioactive coating scaffolds and neural stem cells for spinal cord injury repair
- Open Access
- 1 October 2024
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 19, 10885-10898
PKH Dyes Should Be Avoided in the EVs Biodistribution Study of the Brain: A Call for Caution
Introduction: Extracellular vesicles (EVs) are nanosized membrane vesicles that are naturally secreted by almost all cells and have gained considerable attention. Many studies have applied EVs to the treatment of brain diseases and validated their effectiveness. Although only a few EVs can penetrate the blood‒brain barrier (BBB) into the brain after administration, it has been proven that EVs and their cargos exert their effects by interacting with brain cells. PKH dyes are commonly used to stain EVs for distribution studies. However, systematic investigations of imaging characteristics of the PKH-labeled EVs distributed in the brain are still scarce. Methods: We stained EVs derived from mesenchymal stem cells with PKH26 or PKH67. PKH26-labeled EVs and PKH67-labeled EVs were administered at the same time into each mouse while PKH26-labeled EVs were given through tail veins and PKH67-labeled EVs were given through intraperitoneal injection. Confocal microscopy was used to explore the distribution difference of two types of EVs given via different routes in the brain. Results: The fluorescence of PKH26 and PKH67 had nearly identical distributions in brain slices after 1 h, 6 h, 12 h and 1 day of EV administration. Under the same confocal parameters, brain slices without EVs administration demonstrated the same result. However, liver slices from mice administered with labeled EVs showed obviously different distributions of two types PKH fluorescence. Discussion: These findings raise questions about the ability of PKH dyes as labels for EVs when explore the EV brain distribution observed via confocal microscopy.
- 1 October 2024
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 19, 10885-10898
Open AccessPKH Dyes Should Be Avoided in the EVs Biodistribution Study of the Brain: A Call for Caution
Introduction: Extracellular vesicles (EVs) are nanosized membrane vesicles that are naturally secreted by almost all cells and have gained considerable attention. Many studies have applied EVs to the treatment of brain diseases and validated their effectiveness. Although only a few EVs can penetrate the blood‒brain barrier (BBB) into the brain after administration, it has been proven that EVs and their cargos exert their effects by interacting with brain cells. PKH dyes are commonly used to stain EVs for distribution studies. However, systematic investigations of imaging characteristics of the PKH-labeled EVs distributed in the brain are still scarce. Methods: We stained EVs derived from mesenchymal stem cells with PKH26 or PKH67. PKH26-labeled EVs and PKH67-labeled EVs were administered at the same time into each mouse while PKH26-labeled EVs were given through tail veins and PKH67-labeled EVs were given through intraperitoneal injection. Confocal microscopy was used to explore the distribution difference of two types of EVs given via different routes in the brain. Results: The fluorescence of PKH26 and PKH67 had nearly identical distributions in brain slices after 1 h, 6 h, 12 h and 1 day of EV administration. Under the same confocal parameters, brain slices without EVs administration demonstrated the same result. However, liver slices from mice administered with labeled EVs showed obviously different distributions of two types PKH fluorescence. Discussion: These findings raise questions about the ability of PKH dyes as labels for EVs when explore the EV brain distribution observed via confocal microscopy.
- Open Access
- 24 August 2023
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 15, 1237532
The effect of different sources of mesenchymal stem cells on microglia states
Microglial reaction plays a key role in the prognosis of traumatic CNS injuries (TBI and SCI). A growing number of studies have shown that mesenchymal stem cells (MSCs) play an important role in regulating microglial states. This review summarizes the effects and mechanisms of different sources of MSCs on microglial states in the last 5 years. In general, bone marrow-derived mesenchymal stem cells are the most accessible and widely used, and can produce immunosuppressive effects on a variety of brain injuries including TBI through tissue engineering in situ implantation; MSCs mainly regulate inflammatory pathways and promote the states of microglia in the anti-inflammatory direction, which also secrete certain cytokines or extracellular vesicles to affect apoptotic pathways, such as the extracellular vesicles miR-21-5p, acting as a neuronal protector.
- 24 August 2023
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 15, 1237532
Open AccessThe effect of different sources of mesenchymal stem cells on microglia states
Microglial reaction plays a key role in the prognosis of traumatic CNS injuries (TBI and SCI). A growing number of studies have shown that mesenchymal stem cells (MSCs) play an important role in regulating microglial states. This review summarizes the effects and mechanisms of different sources of MSCs on microglial states in the last 5 years. In general, bone marrow-derived mesenchymal stem cells are the most accessible and widely used, and can produce immunosuppressive effects on a variety of brain injuries including TBI through tissue engineering in situ implantation; MSCs mainly regulate inflammatory pathways and promote the states of microglia in the anti-inflammatory direction, which also secrete certain cytokines or extracellular vesicles to affect apoptotic pathways, such as the extracellular vesicles miR-21-5p, acting as a neuronal protector.
- RetractedOpen Access
- 8 August 2022
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 5079153
[Retracted] Recent Advances in Cell and Functional Biomaterial Treatment for Spinal Cord Injury
Spinal cord injury (SCI) is a devastating central nervous system disease caused by accidental events, resulting in loss of sensory and motor function. Considering the multiple effects of primary and secondary injuries after spinal cord injury, including oxidative stress, tissue apoptosis, inflammatory response, and neuronal autophagy, it is crucial to understand the underlying pathophysiological mechanisms, local microenvironment changes, and neural tissue functional recovery for preparing novel treatment strategies. Treatment based on cell transplantation has become the forefront of spinal cord injury therapy. The transplanted cells provide physical and nutritional support for the damaged tissue. At the same time, the implantation of biomaterials with specific biological functions at the site of the SCI has also been proved to improve the local inhibitory microenvironment and promote axonal regeneration, etc. The combined transplantation of cells and functional biomaterials for SCI treatment can result in greater neuroprotective and regenerative effects by regulating cell differentiation, enhancing cell survival, and providing physical and directional support for axon regeneration and neural circuit remodeling. This article reviews the pathophysiology of the spinal cord, changes in the microenvironment after injury, and the mechanisms and strategies for spinal cord regeneration and repair. The article will focus on summarizing and discussing the latest intervention models based on cell and functional biomaterial transplantation and the latest progress in combinational therapies in SCI repair. Finally, we propose the future prospects and challenges of current treatment regimens for SCI repair, to provide references for scientists and clinicians to seek better SCI repair strategies in the future.
- 8 August 2022
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 5079153
RetractedOpen Access[Retracted] Recent Advances in Cell and Functional Biomaterial Treatment for Spinal Cord Injury
Spinal cord injury (SCI) is a devastating central nervous system disease caused by accidental events, resulting in loss of sensory and motor function. Considering the multiple effects of primary and secondary injuries after spinal cord injury, including oxidative stress, tissue apoptosis, inflammatory response, and neuronal autophagy, it is crucial to understand the underlying pathophysiological mechanisms, local microenvironment changes, and neural tissue functional recovery for preparing novel treatment strategies. Treatment based on cell transplantation has become the forefront of spinal cord injury therapy. The transplanted cells provide physical and nutritional support for the damaged tissue. At the same time, the implantation of biomaterials with specific biological functions at the site of the SCI has also been proved to improve the local inhibitory microenvironment and promote axonal regeneration, etc. The combined transplantation of cells and functional biomaterials for SCI treatment can result in greater neuroprotective and regenerative effects by regulating cell differentiation, enhancing cell survival, and providing physical and directional support for axon regeneration and neural circuit remodeling. This article reviews the pathophysiology of the spinal cord, changes in the microenvironment after injury, and the mechanisms and strategies for spinal cord regeneration and repair. The article will focus on summarizing and discussing the latest intervention models based on cell and functional biomaterial transplantation and the latest progress in combinational therapies in SCI repair. Finally, we propose the future prospects and challenges of current treatment regimens for SCI repair, to provide references for scientists and clinicians to seek better SCI repair strategies in the future.
- 14 July 2022
- Published by Springer Nature in Journal of Materials Science
- Vol. 57 (28) , 13632-13646
Biodegradable GdPO4·H2O/PLGA microcarriers for stem cell delivery and non-invasive MRI translocation tracing
- 14 July 2022
- Published by Springer Nature in Journal of Materials Science
- Vol. 57 (28) , 13632-13646
Biodegradable GdPO4·H2O/PLGA microcarriers for stem cell delivery and non-invasive MRI translocation tracing
- Open Access
- 13 July 2022
- Published by Elsevier in Acta Biomaterialia
- Vol. 150, 67-82
Bioorthogonal DOPA-NGF activated tissue engineering microunits for recovery from traumatic brain injury by microenvironment regulation
- 13 July 2022
- Published by Elsevier in Acta Biomaterialia
- Vol. 150, 67-82
Open AccessBioorthogonal DOPA-NGF activated tissue engineering microunits for recovery from traumatic brain injury by microenvironment regulation
- Open Access
- 10 February 2022
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 16, 814684
Traumatic Brain Injury Is Associated With Both Hemorrhagic Stroke and Ischemic Stroke: A Systematic Review and Meta-Analysis
Background: Traumatic brain injury (TBI) is considered a risk factor for the development of stroke (Hemorrhagic Stroke and Ischemic Stroke). We performed this systemic review and meta-analysis to determine the association of prior TBI with the subsequent diagnosis of stroke.Methods: We systematically searched PubMed, EMBASE, and the Cochrane Library for cohort studies involving TBI patients who subsequently developed stroke. Study selection, data extraction, and quality assessment were performed by two separate researchers. Data were analyzed with random-effects models, and a secondary analysis stratified by the type of stroke was performed.Results: Of the 741 identified studies, 6 studies were eligible for inclusion, with more than 2,200,000 participants. TBI predicted the occurrence of stroke in the random-effect model, with a relative risk of 2.14 (95% CI 1.97–2.32, P < 0.001). Furthermore, in the analysis of each type of stroke, TBI was associated with the incidence of ischemic stroke (RR 1.351 95% CI 1.212–1.506, P < 0.001), and TBI was associated with an even greater increase in the incidence of hemorrhagic stroke (RR 6.118 95% CI 5.265–7.108, P < 0.001).Conclusion: Our meta-analysis showed that TBI was associated with a more than two-fold increase in the risk of stroke. However, owing to the high degree of heterogeneity, decisions should be made on a patient-by-patient basis. The occurrence of TBI is associated with the development of both hemorrhagic and ischemic stroke, and the risk of hemorrhagic stroke is much higher than that of ischemic stroke in TBI patients.
- 10 February 2022
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 16, 814684
Open AccessTraumatic Brain Injury Is Associated With Both Hemorrhagic Stroke and Ischemic Stroke: A Systematic Review and Meta-Analysis
Background: Traumatic brain injury (TBI) is considered a risk factor for the development of stroke (Hemorrhagic Stroke and Ischemic Stroke). We performed this systemic review and meta-analysis to determine the association of prior TBI with the subsequent diagnosis of stroke.Methods: We systematically searched PubMed, EMBASE, and the Cochrane Library for cohort studies involving TBI patients who subsequently developed stroke. Study selection, data extraction, and quality assessment were performed by two separate researchers. Data were analyzed with random-effects models, and a secondary analysis stratified by the type of stroke was performed.Results: Of the 741 identified studies, 6 studies were eligible for inclusion, with more than 2,200,000 participants. TBI predicted the occurrence of stroke in the random-effect model, with a relative risk of 2.14 (95% CI 1.97–2.32, P < 0.001). Furthermore, in the analysis of each type of stroke, TBI was associated with the incidence of ischemic stroke (RR 1.351 95% CI 1.212–1.506, P < 0.001), and TBI was associated with an even greater increase in the incidence of hemorrhagic stroke (RR 6.118 95% CI 5.265–7.108, P < 0.001).Conclusion: Our meta-analysis showed that TBI was associated with a more than two-fold increase in the risk of stroke. However, owing to the high degree of heterogeneity, decisions should be made on a patient-by-patient basis. The occurrence of TBI is associated with the development of both hemorrhagic and ischemic stroke, and the risk of hemorrhagic stroke is much higher than that of ischemic stroke in TBI patients.